Heterogeneity of CCK-B receptors involved in animal models of anxiety
References (51)
- et al.
Enzyme-resistant CCK analogs with high affinities for central receptors
Peptides
(1988) - et al.
Characteristics of 125I-Bolton-Hunter labelled cholecystokinin binding in human brain
Neuropeptides
(1988) - et al.
CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens
Pharmacol. Biochem. Behav.
(1989) - et al.
Methods and methodological considerations in measuring anti-anxiety effects of tranquilizing drugs
Prog. Neuro-Psychol.
(1980) - et al.
Occurrence of two cholecystokinin binding sites in guinea pig brain cortex
Biochem. Biophys. Res. Commun.
(1986) - et al.
Characterization of [3H]CCK4 binding sites in mouse and rat brain
Neuropeptides
(1988) - et al.
Characterization and visualization of cholecystokinin receptors in rat brain using [3H]pentagastrin
Peptides
(1983) - et al.
Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat
Eur. J. Pharmacol.
(1991) - et al.
The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization
J. Biol. Chem.
(1993) - et al.
Two brain cholecystokinin receptors: Implications for behavioral actions
Brain Res.
(1986)
LIGAND: a versatile computerized approach for the characterization of ligand binding systems
Anal. Biochem.
Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329
Neuropharmacology
Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
J. Neurosci. Methods
Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization
Biochem. Biophys. Res. Commun.
Anxiolytic effect of CCK-antagonists on plus-maze behavior in mice
Brain Res.
Cholecystokinin and anxiety
Trend Pharmacol. Sci.
Synthesis and biological activity of Boc[Nle28, Nle31]CCK27–33 a highly potent CCK8 analogue
Peptides
Effect of a highly selective central CCK-B receptor agonist: BC-264 on rat sleep
Pharmacol. Biochem. Behav.
Anti-exploratory effect of in elevated plus-maze. Involvement of NMDA and CCK receptors
Eur. Neuropsychopharmacol.
Opioid σ receptor subtypes are associated with different potassium channels
Eur. J. Pharmacol.
Brain CCK receptors: Species differences in regional distribution and selectivity
Peptides
Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings
Arch. Gen. Psychiatry
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260
J. Med. Chem.
Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist
Cyclic cholecystokinin analogues with high selectivity for central receptors
Cited by (81)
Recent advancements on the synthesis and biological significance of pipecolic acid and its derivatives
2022, Journal of Molecular StructureCitation Excerpt :S-proline, on the other hand, largely produced the syn product in the same reaction. According to computational studies, Pip has a lower energy preference than proline for transition scaffolds comprising the S-trans enamine and S-cis enamine, leading to syn- and anti-Mannich products as shown in Scheme 23 [135]. In 2008, Kumar et al. reported a solvent-free, three-component coupling process using substituted cinnamaldehyde 90, aniline 92, and ethyl acetoacetate 91 with Pip as a catalyst to produce 1,4-dihydropyridine 93 in a single pot.
Non-sulfated cholecystokinin-8 reduces meal size and prolongs the intermeal interval in male Sprague Dawley rats
2019, NeuropeptidesCitation Excerpt :Similar experiments are needed to demonstrate a peripheral site of action regulating reduction of food intake by NS CCK-8. Finally, a central site of action for NS CCK-8 is plausible for other physiological responses evoked by this peptide e.g. anxiety (Derrien et al., 1994; Costall et al., 1991; Singh et al., 1991) and stimulation of gastric acid secretion (Prinz et al., 1993; Sandvik & Waldum, 1991). However, as mentioned earlier the current study is the first systematic study in the literature that shows a satiety effect by NS CCK-8.
Neuropeptide Y attenuates anxiety- and depression-like effects of cholecystokinin-4 in mice
2014, NeuroscienceCitation Excerpt :I.c.v. administration of CCK-4 significantly increased the immobility time in FST, suggesting a depressive role of CCK-4. This observation is in accordance with the earlier report (Derrien et al., 1994), wherein CCK-B receptor antagonist showed antidepressant effect in the FST model in mice. CCK-B receptor agonist BC 264, increased depression-like response in mice following inescapable electric shocks and the same were prevented by the selective CCK-B receptor antagonist L-365260 (Hernando et al., 1994).
Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y
2012, Physiology and BehaviorCitation Excerpt :CCK is synthesized as a 115 amino acid preprohormone and is converted into multiple isoforms. The predominant form of CCK in the CNS is a sulfated octapeptide, CCK-8S, however, CCK-8 nonsulphated, CCK-5, and CCK-4 isoforms exist in lesser concentrations within the brain [33,34]. There are two CCK receptors — CCK-A and CCK-B.
Lesions of the nucleus accumbens shell can reduce activity in the elevated plus-maze
2007, Progress in Neuro-Psychopharmacology and Biological PsychiatryCholecystokinin and endogenous opioid peptides: Interactive influence on pain, cognition, and emotion
2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry